If you’re on the hunt for stocks to watch today, Puma Biotechnology, Inc. (NASDAQ:PBYI) is a stock to give close attention to. The company shares are trading 5.13% or 0.48 points down from last closing price of $9.35, reaching $8.87 at last check. The PBYI share price has dropped in 3 of the last 5 days and is down -10.35% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -2,441,720 shares, and in total 1.059 million shares valued at $9.398 million were seen changing hands compared with 3.501 million shares valued at $32.736 million recorded at the previous session. You should take into consideration that a falling volume on lower prices shows the bearish trend but this is an early indication which means that the PBYI stock is near its bottom.
Puma Biotechnology, Inc. (PBYI) shares have notched a 3-month decline of about -10.35%, but has still tumbled -54.05% year to date. By comparison, the stock sank -59.77% over the past 12 months, while it jumped 31.14% over the 1 month. The company’s market cap is around $352.4M, with its short interest ratio standing at 3.97%.
In the current trading session for PBYI, the stock witnessed two major price actions, it rose to a high of $9.61 and was down as much as $8.85 at one point. The high recorded is very low when compared to their 52-week high which is $6.26. The 52-week high is now at -79.21 distance from current price. Their recent low of $43.9 represents a 45.77% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for PBYI is $11.71, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
The stock of Puma Biotechnology, Inc. earned $-2.47 per share in the trailing 12 months and has a P/E ratio of -3.59. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 25.68 and lower compared to the sector’s average of 33.17. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. PBYI also has P/S multiple of 1.19. This is smaller versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 2.79x.
PBYI‘s last price was down -48.27% as compared to the average trading price of 50 days recorded at $17.15 while enlarging the period to 200 trading days, the average closing price was $8.21. At present, there are 37.69 million in the total number of common shares owned by the public and among those 34.62 million shares have been available to trade. The percentage of shares being held by the company management was 11.3% while institutions stake was 97%. The company has generated negative returns on equity over the last 12 months (-325.9%). It managed to keep its gross profit margin at 86.8% over the past 12 months.
When assessing the full upside of the PBYI stock, there is another set of technicals that should be looked into and considered. Its 5.48% gain from moving average of $8.41 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 1.67 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of Puma Biotechnology, Inc. — 0 analysts rate the stock as a buy with another 0 rating it strong buy. There are 6 analysts who maintain a hold rating for the stock, with 3 giving it a sell rating. Analysts arrived at a 12-month price target of $14.13 on shares of Puma Biotechnology, Inc. (NASDAQ:PBYI), which corresponds to 54.71% upside potential than its current market price of $8.87 and implies potential despite the recent drop in the price. However, their current target price has fallen from $17.25 a month ago and is down handily from the consensus target of $19.25 a quarter ago.
In the last five years, the EPS of the company has been roughly -9.5%. Though the percentage looks disappointing, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has retreated at an average annualized rate of about 0 over the last five years. The company recently recorded a drop of -9.9%, but this figure is rather unattractive.
Let’s briefly check the hedge fund interest towards PBYI stock. Metropolitan Life Insurance Co NY added position in the company after it grew 14% or 9,311 shares of its common stock. The hedge fund now owns 10,615 shares worth $94,155, SEC documents show. Millennium Management LLC shored up assets in the stock as 453714 shares have been purchased, increasing its stake by 49.3% to 677,395 shares which are currently valued at $6,008,494. In addition, Partner Investment Management L.P. recently reported that it now owns 33,866 shares making a total of $300,391 based on the recent price. This refelects a change of 22.8% in their ownership.